Challenges associated with non-oral pulmonary arterial hypertension treatments, Aldo Aguirre-Camacho, Therapeutic Advances in Respiratory Disease

A study titled “Patients’ perspectives on the challenges associated with receiving non-oral pulmonary arterial hypertension treatment: a mixed methods study”, by Aldo Aguirre-Camacho, was published on “Therapeutic Advances in Respiratory Disease” on November 21, 2024. The study investigates how non-oral treatments for pulmonary arterial hypertension impact patients’ quality of life beyond the challenges posed by […]

Challenges associated with non-oral pulmonary arterial hypertension treatments, Aldo Aguirre-Camacho, Therapeutic Advances in Respiratory Disease Read Post »

Pulmonary Hypertension: From Therapeutic Nihilism to Multiple Therapeutic Interventions, Vallerie V. McLaughlin, Marc Humbert, “Circulation”, November 18, 2024

This article, titled “Pulmonary Hypertension: From Therapeutic Nihilism to Multiple Therapeutic Interventions”, published on November 18, 2024 on Circulation, is undoubtedly encouraging and hopeful, showcasing the tremendous progress made in the field of pulmonary hypertension. It highlights how far we’ve come, from no treatments to over a dozen targeted therapies addressing multiple pathways, improving the

Pulmonary Hypertension: From Therapeutic Nihilism to Multiple Therapeutic Interventions, Vallerie V. McLaughlin, Marc Humbert, “Circulation”, November 18, 2024 Read Post »

Prostacyclins Show New Hope for Inoperable CTEPH Patients: Meta-analysis Insights, Marisa Wexler, Pulmonary Hypertension News, November 6, 2024

A recent article on Pulmonary Hypertension News reports on the findings of a meta-analysis which suggest that prostacyclin pathway-targeting therapies hold promise for treating chronic thromboembolic pulmonary hypertension (CTEPH), particularly patients who are ineligible for surgery or experience persistent/recurrent symptoms after surgical intervention. However, the authors emphasize the need for larger-scale studies to confirm the

Prostacyclins Show New Hope for Inoperable CTEPH Patients: Meta-analysis Insights, Marisa Wexler, Pulmonary Hypertension News, November 6, 2024 Read Post »

SGLT2 Inhibitors (originally designed for treating diabetes-2) show potential to boost survival in pulmonary arterial hypertension patients, Isabella Hornick, “Healio”, October 2024

An article by medical journalist Isabella Hornick recently published on “Healio” reports on a retrospective study which suggests that sodium-glucose cotransporter-2 (SGLT2) inhibitors may significantly reduce all-cause mortality in patients with pulmonary arterial hypertension (PAH). While these findings are promising, further prospective clinical trials are needed to confirm the results and address potential biases, according

SGLT2 Inhibitors (originally designed for treating diabetes-2) show potential to boost survival in pulmonary arterial hypertension patients, Isabella Hornick, “Healio”, October 2024 Read Post »

New research published in “The Lancet” suggests that the seratonin pathway might not be a suitable option for pulmonary arterial hypertension therapy, September 19, 2024

New research published in The Lancet on September 19, 2024, suggests that the seratonin pathway might not be a suitable option for pulmonary arterial hypertension therapy. The role of serotonin in pulmonary arterial hypertension has been extensively studied in recent decades, with preclinical data indicating involvement in disease pathogenesis; however, clinical studies up to now

New research published in “The Lancet” suggests that the seratonin pathway might not be a suitable option for pulmonary arterial hypertension therapy, September 19, 2024 Read Post »

“A new day has come: Sotatercept for the treatment of pulmonary arterial hypertension”, The Journal of Heart and Lung Transplantation, October 4, 2024

A new day has come: Sotatercept for the treatment of pulmonary arterial hypertension”, The Journal of Heart and Lung Transplantation , October 4, 2024: a state-of-the-art review which summarizes the current understanding of the mechanism of action of sotatercept, the impact on outcomes that improve how patients feel, function, and survive, and the safety and

“A new day has come: Sotatercept for the treatment of pulmonary arterial hypertension”, The Journal of Heart and Lung Transplantation, October 4, 2024 Read Post »

A Belgian consensus paper on sotatercept for the treatment of pulmonary arterial hypertension, “Acta Cardiologica”, October 4, 2024

A new study published in Acta cardiologica on October 4, 2024, reviews the current evidence on sotatercept and provides a Belgian perspective on its place in the future treatment strategy for pulmonary arterial hypertension. We are delighted to see that two patients from Belgium are included as co-authors. Wendy Vansteenkiste is the President of the

A Belgian consensus paper on sotatercept for the treatment of pulmonary arterial hypertension, “Acta Cardiologica”, October 4, 2024 Read Post »

New research suggests that the serotonin pathway might not be a suitable option for pulmonary arterial hypertension therapy, The Lancet Respiratory Medicine, September 19, 2024

The role of serotonin in pulmonary arterial hypertension has been extensively studied in recent decades, with preclinical data indicating involvement in disease pathogenesis; however, clinical studies have yielded mixed results. New research published in The Lancet suggests that the seratonin pathway might not be a suitable option for pulmonary arterial hypertension therapy. ELEVATE-2 was a

New research suggests that the serotonin pathway might not be a suitable option for pulmonary arterial hypertension therapy, The Lancet Respiratory Medicine, September 19, 2024 Read Post »

Medication adherence in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), European Respiratory Review, September 2024

An article titled “Medication adherence, related factors and outcomes among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: a systematic review”, was recently published in the European Respiratory Review. It investigates medication adherence (MA) in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). The authors note that while it

Medication adherence in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), European Respiratory Review, September 2024 Read Post »

New study finds that elevated “asporin” levels in pulmonary arterial hypertension lung samples are linked to lower disease severity, Healio news, October 2, 2024

In pulmonary arterial hypertension lung samples researchers have observed elevated asporin levels and found a link between these levels and lower disease severity. Higher levels of asporin appeared to counteract the pathological remodeling of the pulmonary vasculature that characterizes pulmonary arterial hypertension. Jason Hong, MD, PhD, assistant clinical professor at David Geffen School of Medicine

New study finds that elevated “asporin” levels in pulmonary arterial hypertension lung samples are linked to lower disease severity, Healio news, October 2, 2024 Read Post »

Results of the INSIGNIA-PAH study on MK-5475, an inhaled soluble guanylate cyclase stimulator for pulmonary arterial hypertension, published on the ERS Respiratory Journal, Vol 64 Issue 3, 2024

MK-5475 is an experimental soluble guanylate cyclase stimulator which is administered via dry powder inhalation and is designed to potentially mitigate the side effects associated with systemic vasodilation. The results of the INSIGNIA-PAH study published in the Respiratory Journal suggest that MK-5475 reduced pulmonary vascular resistance (PVR) and was well tolerated in patients with pulmonary

Results of the INSIGNIA-PAH study on MK-5475, an inhaled soluble guanylate cyclase stimulator for pulmonary arterial hypertension, published on the ERS Respiratory Journal, Vol 64 Issue 3, 2024 Read Post »

Single tablet combination macitentan and tadalafil for pulmonary arterial hypertension (PAH) receives EU Commission approval, September 30, 2024

Janssen-Cilag International NV, a Johnson & Johnson company, announced on September September 30, 2024, that the European Commission has approved Yuvanci®, a single tablet macitentan 10 mg and tadalafil 40 mg combination therapy for the long-term treatment of adult pulmonary arterial hypertension patients in WHO Functional Class II-III, who are treated with macitentan and tadalafil

Single tablet combination macitentan and tadalafil for pulmonary arterial hypertension (PAH) receives EU Commission approval, September 30, 2024 Read Post »

“Serotonin pathway blockade in pulmonary arterial hypertension”, The Lancet Respiratory Medicine, September 19, 2024

Article exploring the serotonin pathway in pulmonary arterial hypertension care published in The Lancet Respiratory Medicine on September 19, 2024, titled “Serotonin pathway blockade in pulmonary arterial hypertension”. The author is Marcin Kurzyna, MD, PhD, FESC Citation Serotonin pathway blockade in pulmonary arterial hypertension, Kurzyna, Marcin, The Lancet Respiratory Medicine, Volume 0, Issue 0, DOI: 10.1016/S2213-2600(24)00291-1

“Serotonin pathway blockade in pulmonary arterial hypertension”, The Lancet Respiratory Medicine, September 19, 2024 Read Post »

Oral anticoagulant treatment in the era of multi-drug therapies for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), Blood Review, September 4, 2024

The use of oral anticoagulants in the management of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) is the object of an article published in “Blood Reviews” on 4 September 2024 which examines the current evidence on oral anticoagulant use in PAH and CTEPH and discusses the implications of drug-drug interactions within the current

Oral anticoagulant treatment in the era of multi-drug therapies for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), Blood Review, September 4, 2024 Read Post »

U.S. Food and Drug Administration (FDA) grants tentative approval of YUTREPIA™ (treprostinil) inhalation powder for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)

Liquidia Corporation announced on August 20, 2024, that the US Food and Drug Administration (FDA) has granted tentative approval for YUTREPIA™ (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The approval is supported by the Phase 3 INSPIRE trial, which demonstrated YUTREPIA’s safety and tolerability.

U.S. Food and Drug Administration (FDA) grants tentative approval of YUTREPIA™ (treprostinil) inhalation powder for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) Read Post »

Practical management of oral treprostinil in patients with pulmonary arterial hypertension: Lessons from ADAPT, EXPEDITE, and expert consensus, “Respiratory Medicine”

Oral treprostinil is a prostacyclin analogue approved to treat pulmonary arterial hypertension (PAH). A study analysing the practical management of oral treprostinil in patients with pulmonary arterial hypertension has been published on “Respiratory Medicine” Volume 231, 107734, September 2024. The article is based on results of the ADAPT and EXPEDITE trials and expert consensus. The

Practical management of oral treprostinil in patients with pulmonary arterial hypertension: Lessons from ADAPT, EXPEDITE, and expert consensus, “Respiratory Medicine” Read Post »

The US Food and Drug Administration (FDA) grants orphan drug designation to ZMA001, a monoclonal antibody being developed as a first-in-class treatment for pulmonary arterial hypertension

The US Food and Drug Administration (FDA) has granted orphan drug designation to ZMA001,a first-in-class therapeutic monoclonal antibody designed to control or inhibit inflammation responses in pulmonary blood vessels. ZMA001 could potentially improve both the survival rates and the quality of life of patients by addressing the underlying cause of pulmonary arterial hypertension. The placebo-controlled

The US Food and Drug Administration (FDA) grants orphan drug designation to ZMA001, a monoclonal antibody being developed as a first-in-class treatment for pulmonary arterial hypertension Read Post »

Selexipag in patients with pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD): Real-world experience from the EXPOSURE study, Pulmonary Circulation, July 28 2024

Selexipag shows promise for treating pulmonary arterial hypertension associated with connective tissue disease (CTD). The ongoing EXPOSURE (EUPAS19085) study sheds light on the real-world management of PAH-CTD patients in Europe and Canada. For more detailed insights, check out the full study results at this link on PubMed Citation Gaine S, Escribano-Subias P, Muller A, Fernandes

Selexipag in patients with pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD): Real-world experience from the EXPOSURE study, Pulmonary Circulation, July 28 2024 Read Post »

“How We Do It: Using Sotatercept in the Care of Patients with Pulmonary Arterial Hypertension”, CHEST Journal, July 14, 2024

Sotatercept, an activin signaling inhibitor, has been recently approved by the FDA for treating pulmonary arterial hypertension (PAH) (see our recent article about the FDA approval at this link), based on two pivotal clinical trials. The authors of the article titled “How We Do It: Using Sotatercept in the Care of Patients with Pulmonary Arterial

“How We Do It: Using Sotatercept in the Care of Patients with Pulmonary Arterial Hypertension”, CHEST Journal, July 14, 2024 Read Post »

The UK Pulmonary Hypertension Association Chair, Dr Iain Armstrong, explains what happens next with sotatercept and what will be considered when it comes to making decisions for the UK

The first-in-class pulmonary arterial hypertension drug sotatercept was approved in March 2024 by the Food and Drug Administration (FDA) in the USA and the approval of the European Medicines Agency (EMA) is expected in the next few months. The UK Pulmonary Hypertension Association, PHA UK, has put together a short video, with its Chair Dr

The UK Pulmonary Hypertension Association Chair, Dr Iain Armstrong, explains what happens next with sotatercept and what will be considered when it comes to making decisions for the UK Read Post »

TRANSLATE »
Scroll to Top